Kornimate/medical-research-clean huggingface dataset:
customised mouthguards on baseball and softball performance

Conditions: Oral Manifestations; Control Condition

Summary: whether the use of customised mouthguards is effective in improving the athletic performance of baseball and softball performance

this study recruited 45 baseball and softball players, including 30 fielders and 15 pitchers. using a randomized crossover experimental design, the study was divided into randomised divided into customised mouthguards trial (mg) and control trial (con) without temporal positioning. after the participants wore the mouthguard, they performed the vertical jump and grip strength tests sequentially. at the end of the test, depending on the pitcher or fielder, a baseball pitching ability test or a hitting ability test was conducted using a radar baseball tracking system. it is expected to analyze the vertical jump height, grip strength, pitchers' straight and changeup ball speeds, rotation speeds, degree of displacement, on-base and off-base locations. hitting ability was expected to be documented with respect to initial velocity, elevation, and consistency of elevation.

Eligibility criteria:
inclusion criteria: * has won the top 8 national level baseball of softball championships in the last three years. * no cardiovascular and joint diseases. * aged 20 or above who are adults * continuing to train professionally more than 5 days a week for the past year exclusion criteria: * have not won the top 8 national baseball or softball championships in the past three years. * have a cardiovascular or joint disease, or any injuries that may be impaired by exercise. * participants who are underage or not in regular baseball or softball training * have injury to the temporomandibular joint.

Keywords: concurrent activation potentiation bite force
the impact of family integrated care on extrauterine growth restriction at discharge in very low birth weight infants

Conditions: Very Low Birth Weight Infant

Summary: to explore the influence of multi-angle factors, including family integrated care, on extrauterine growth restriction at discharge of very low birth weight infants.

to explore the influence of multi-angle factors, including family integrated care, on extrauterine growth restriction at discharge of very low birth weight infants.very low birth weight infants admitted to 17 neonatal intensive care units in 8 provinces and cities in southeast china from february 2021 to november 2023 were retrospectively included, which were divided into case group and control group according to whether there was extrauterine growth restriction (defined as the weight below the 10th percentile of children of the same age at discharge). the general situation at birth, the length of hospital stay, the incidence of complications during hospital stay, the feeding situation, the length of family participation care and the perinatal situation of the mother were compared between the two groups. the generalized linear mixed model was used to analyze the influencing factors of extrauterine growth retardation at discharge, and the results of influencing factors were visualized by graphpad prism 9.0 software.

Eligibility criteria:
inclusion criteria: 1. newborns admitted to 17 units in 8 provinces from february 2021 to november 2023; 2. birth weight \< 1500 g, gestational age \< 32 weeks; 3. admitted in nicu within 24 hours after birth; 4. premature infants without complications (including bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, intraventricular hemorrhage and late-onset septicemia) at the time of admission. exclusion criteria: 1. death occurred during hospitalization; 2. incomplete outcome data (lack of eugr data at discharge).

Keywords: very low birth weight infants family integrated care
vibrotactile feedback belt in patients with unilateral vestibular hypofunction (uvh)

Conditions: Vestibular Disorder

Summary: the goal of this clinical trial is to study the impact of a continuous vibrotactile feedback belt on balance, (fear of) falling, fatigue and overall functioning in participants with chronic disabling unilateral vestibular hypofunction. the main questions it aims to answer are: • does wearing a vibrotactile feedback belt during waking hours for a week improve sense of balance and mobility, fear of falling, fatigue and overall functioning • does wearing a vibrotactile feedback belt influence static and dynamic balance and gait performance during balance and gait testing. participants will goes through different phases in an randomized order; a baseline phase, a sham phase (i.e., wearing the balancebelt while it is switched off) and an intervention phase (i.e., wearing the balancebelt while it is switched on). it is expected that, just as with patients with bilateral loss of the balance organ, patients with a unilateral loss will also benefit from the balancebelt.


Eligibility criteria:
inclusion criteria: * diagnosed with severe unilateral vestibular dysfunction (i.e., a gain below 0.6 of the affected side and a gain between 0.8 and 1.1 of the contralateral side measured by the video-head impulse test (vhiit)). * duration of dizziness complaints \>3 months (i.e. chronic dizziness). * self-reported imbalance with a fear of falling and/or actual falls. * is able to walk (with or without a walking aid). * self-reported overall mobility and balance score (mbs) of 3-5 points * motivated to try the balancebelt. * provides written informed consent. exclusion criteria: * age \< 18 years * presence of neurological, psychiatric or orthopaedic disorders, persistent postural-perceptual dizziness (pppd), reduced proprioceptive sensitivity or impaired vision which influences the postural stability. * not able to understand instructions and questionnaires in dutch * not able/willing to visit gelre hospital apeldoorn for necessary visits. * wheelchair bound at home

Keywords: vibrotactile feedback
a comparative study of the effects of qs-m needle free injector and glargine pen subcutaneous injection of insulin glargine on insulin use

Conditions: Type 2 Diabetes Mellitus

Summary: a clinical study of the use of glargine insulin in 2 subjects with type two diabetes in china was carried out. the two kinds of injection methods were evaluated as subcutaneous injection of insulin glargine.


Eligibility criteria:
inclusion criteria: 1. male or female aged 18-70 years of age, women of childbearing age need to take adequate contraceptive measures to minimize the risk of pregnancy; 2. the standard of diagnosis of type 2 diabetes and the course of the disease is more than half a year; 3. 18 kg/m2 = bmi = 30kg/m2; 4. received daily injections of insulin glargine and also take one to three kinds of oral medicine (not including secretagogues) patients, daily insulin glargine total dose more than 12iu but \<50iu, the use of insulin glargine than in january; 5. the blood glucose in the fasting vein was in 5.0-9.0mmol/l; 6. the letter of informed consent has been read and signed. exclusion criteria: 1. there is conflict of interest with this research. 2. blood glucose control is not good enough to participate in this study, such as repeated hypoglycemia, diabetic ketoacidosis or hyperosmolar coma. 3. serious diabetic complications such as diabetic foot, diabetic nephropathy and so on; 4. severe cardiovascular events occurred in the last 6 months. 5. the application of hormone or immunosuppressant, or low immunity defect; 6. the use of non steroidal anti-inflammatory drugs; 7. the use of sulfonylureas and insulin secreting agents; 8. a person with a history of cancer; 9. a history of unstable or rapid progressive renal disease; 10. an unstable history of major mental illness; 11. the history of hemoglobin (such as sickle red cell anemia, thalassemia, iron granulocytic anemia); 12. women who are pregnant or are breastfeeding; 13. in the near future there is a clear infection, such as urinary tract infection and pneumonia; 14. recent important visceral hemorrhage, such as gastric hemorrhage and cerebral hemorrhage, etc. 15. skin diseases such as exfoliative dermatitis, pustular sore and infection of pyogenic bacteria; 16. the history of acute pancreatitis or pancreatectomy; 17. the researchers believe that it may lead to any situation in which the subject is unable to complete the study or may cause significant risk to the subject. 18. the results of the laboratory examination are as follows: a. obvious abnormal liver function or in the active phase of the disease (ast\> 3 times the upper limit of normal alt\> or 3 times the upper limit of normal); the creatinine clearance rate of b. was \<60ml/min; c. anaemia caused by any cause of the disease; the results of pregnancy test in women of childbearing age of d. were positive.

Keywords: glargine insulin qs-m needle free injector
umbilical cord milking in non-vigorous infants

Conditions: Birth Asphyxia

Summary: the investigators will conduct a study of non-vigorous term infants to determine if umbilical cord milking (ucm) results in a lower rate of nicu admissions than early clamping and cutting of the umbilical cord at birth for infants who need resuscitation.

at birth, it is critical that an infant begins breathing quickly. the infant has to switch from relying on the placenta for oxygen to using its lungs for the first time. the currently recommended practice for infants who need resuscitation is to immediately clamp the umbilical cord. animal studies show that clamping the cord before the baby breathes can cause the heart beat to slow and can decrease the amount of blood being pumped out of the heart each minute. this study will test whether infants will benefit from ucm. the cord will be quickly milked four times before cutting and will not delay the resuscitation procedures. this study is important because when there is need for resuscitation, neither ucm or delayed cord clamping, are recommended by national and international organizations due to lack of evidence. yet, several large studies from around the world have identified that infants needing resuscitation are more likely to develop conditions such as cerebral palsy, autism and other developmental problems. the trial is a cluster crossover design in which each hospital will be randomly assigned to use either early cord clamping or ucm for any infant needing resuscitation over a period of 12 months. then sites will change to the other method for an additional 12 months.

Eligibility criteria:
inclusion criteria: * non-vigorous newborns born between 35-42 weeks gestation exclusion criteria: * known major congenital or chromosomal anomalies of newborn * known cardiac defects other than small asd, vsd and pda * complete placental abruption/cutting through the placenta at time of delivery * monochorionic multiples * cord anomaly (i.e. cord avulsion, true knot) * presence of non-reducible nuchal cord * perinatal providers unaware of the protocol * incomplete delivery data * infants born in extremis, for whom additional treatment will not be offered

Keywords: umbilical cord milking immediate cord clamping resuscitation
treatable traits of severe asthma

Conditions: Asthma

Summary: severe or uncontrolled asthma is a complex heterogeneous disease, in which patients may exhibit different types of airway inflammation and often accompany multiple comorbidities and risk factors. identifying potential modifiable factors that influence prognosis, i.e., "treatable traits," and targeting these traits for individualized, bundled management of patients may help improve the quality of life of asthma patients and enhance asthma control levels. this project aims to investigate the distribution of treatable traits in uncontrolled asthma patients in beijing by conducting pulmonary function tests, exhaled nitric oxide tests, blood tests, allergen ige tests, and chest ct scans, as well as detailed questionnaires, on patients from three tertiary hospitals in beijing. the project will also assess the impact of treatable traits on the quality of life or asthma control levels of uncontrolled asthma patients in a multidimensional manner. furthermore, the project will select severe asthma patients and establish an individualized, bundled management model based on the treatable traits of severe asthma, through multidisciplinary consultations and shared decision-making with patients. a randomized, parallel-group clinical trial will then be conducted for six months to confirm whether this management model is superior to conventional management in improving the quality of life or asthma control levels of severe asthma patients. the implementation of this project will establish a new model of individualized management for severe asthma based on treatable traits, thereby improving the management level of severe asthma.


Eligibility criteria:
inclusion criteria * must be at least 18 years old and have resided in beijing for at least 6 months. * must meet the diagnostic criteria for asthma as outlined in the 2023 gina guidelines, have written evidence of variable airflow limitation, and have been receiving asthma treatment for at least 6 months. * must meet one or both of the following criteria as defined in the 2023 gina guidelines for uncontrolled asthma: poor symptom control (defined as an asthma control questionnaire (acq-5) score of 0.75 or higher); frequent acute exacerbations (≥2 per year) requiring oral corticosteroids, or severe acute exacerbations (≥1 per year) requiring emergency or hospitalization. * willing to undergo a multidisciplinary, multi-dimensional evaluation and sign an informed consent form. * must meet the criteria for severe asthma as outlined in the 2023 gina guidelines exclusion criteria * use macrolides within 4 weeks of the screening period * use anti-ige, anti-il-5, or anti-il-5r therapy within 4 weeks of the screening period * use inhaled ics + laba + long-acting muscarinic antagonist (lama) within 4 weeks of the screening period * be allergic to macrolides * have a qtc interval prolongation of \>480ms * take a medication that interacts with azithromycin to prolong the qtc interval or cause existing ecg abnormalities, which may lead to arrhythmias.

Keywords: treatable traits asthma severe aqlq acq
clinical evaluation of the next generation phaco system

Conditions: Cataract

Summary: this study is a prospective, open-label clinical study of the veritas vision system. the study will be conducted at up to three sites, with minimum 55 eyes and up to 150 eyes to be treated. the investigator or designee will perform the cataract surgery with the veritas vision system on the subjects. the data from the system log files, the questionnaire, the operative report and other medical records will be used to assess the clinical utilization of the veritas vision system.


Eligibility criteria:
inclusion criteria: * minimum 22 years of age. * cataracts for which cataract extraction and posterior chamber iol implantation have been planned. * availability, willingness, ability and sufficient cognitive awareness to comply with study requirements, examination procedures, and visits. * be willing to provide informed consent and authorization to disclose protected health information or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical procedures in the governing countries. exclusion criteria: * expected surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled intraocular pressure change, or significant vitreous prolapse or loss). * subjects with only one good eye (e.g. amblyopic condition etc.). * subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to iol decentration, including pseudoexfoliation, trauma, or posterior capsule defects. * history or current use of alpha-1 antagonist medication (e.g., flomax). * any condition which, in the investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study or for which cataract surgery is contraindicated. * pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils). * is pregnant, or is breast feeding, or intend to become pregnant during the study. * concurrent participation or expected participation in an interventional (i.e., surgical or pharmaceutical interventional) clinical trial within 14 days prior to study screening.
radiochemotherapy with panitumumab in the localised epidermoid carcinoma of the anus

Conditions: Epidermoid Carcinoma; Anus

Summary: treatment is based on radiochemotherapy for locally advanced tumours. the objective of treatment is to provide a cure without resorting to abdominoperineal amputation, while preserving sphincter function. the prognosis is mainly related to tumour size and lymph node invasion. the large majority of patients do not show any spread remote from the tumour at the time of diagnosis (2). recurrences are mainly of a local/regional nature and require abdominoperineal amputation. this type of intervention is not always possible or complete, which then gives rise to the particularly distressing risk of local progression, with survival at 3 years of approximately 30% (3). it is therefore very important to achieve a complete and permanent tumour response from initial treatment with radiochemotherapy. furthermore, the use of an anti-egfr antibody in combination with exclusive radiotherapy in ent cancer was able to increase recurrence-free survival and overall survival in these patients. these data are in favour of the use of a combination of chemotherapy and anti-egfr antibodies in epidermoid cancer of the anus.


Eligibility criteria:
inclusion criteria: * histologically proven epidermoid carcinoma of the anus * locally advanced tumour without metastases * stage t2\>3 cm or t3 or t4, irrespective of n * stage n1-n3 irrespective of t stage (t1 to t4) * general condition who 0-1 * life expectancy \> 3 months * signed informed consent form * age \> 18 years * effective contraception in female and/or male patients having reached sexual maturity during treatment and up to 6 months after the end of treatment * cd4 \> 400 / mm3 * measureable tumor on at least one of the following exams : mri, endoscopic ultrasonography, clinical exam exclusion criteria: * presence of metastases * previous anti-egfr therapy * stage t1n0 or t2 \< 3 cm n0 * history of pelvic radiotherapy * at least one of the following laboratory test results: neutrophils \ 1.5 times the upper limit of the normal range, transaminase (asat and alat) \> 2.5 times the upper limit of the normal range, creatinine clearance \< 50 ml/min (cockcroft's formula appendix x), mg2+ \< the lower limit of the normal range, ca2+ \< the lower limit of the normal range * significant coronary artery disease or myocardial infarction in the past year * follow-up not possible due to psychological or geographic reasons * history of interstitial pneumonitis or pulmonary fibrosis * history of malignant disease in the past five years apart from basocellular skin carcinoma or in situ cervical carcinoma having received adequate treatment * pregnant or breast-feeding women, women of child-bearing potential not having taken a pregnancy test.

Keywords: anus carcinoma panitumumab mitomycine 5fu radiotherapy
cancer genetic testing in ethnic populations

Conditions: Breast Carcinoma; Carcinoma of Unknown Primary; Central Nervous System Carcinoma; Digestive System Carcinoma; Genitourinary System Carcinoma; Head and Neck Carcinoma; Malignant Brain Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Musculoskeletal Neoplasm; Malignant Solid Neoplasm; Skin Carcinoma

Summary: this clinical trial examines the integration of cancer genetic testing in various ethnic populations. studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. the information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.

primary objective: i. to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at mayo clinic arizona and mayo clinic florida cancer clinics. secondary objectives: i. perform a chart review to assess the impact of genetic testing as part of standard of oncology care: ia. determine prevalence of pathogenic germline mutation detected by multi-gene panel testing. ib. determine differences in germline mutation detection in these patients as compared to traditional guideline (national comprehensive cancer network \[nccn\]) based approach for genetic evaluation. outline: patients undergo collection of blood or saliva sample for genetic testing.

Eligibility criteria:
inclusion criteria: * patients at least 18 years of age * individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (cns)/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to mayo clinic (mc arizona or mc florida) for clinical management/treatment; and patients receive genetic testing as described above * self-identified as being from various ethnic populations including hispanic/latino, native american/alaskan, african american (including of african descent), asian and other european populations * blood collection is feasible (health, access and/or tolerability) for requested blood sample(s) * individuals have agreed to participate and signed the study informed consent form exclusion criteria: * patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at mayo clinic and available for review by the research coordinator at time of consent * past or current history of hematological cancer (including leukemias, multiple myeloma) * all bone marrow transplants